Advantage Investment Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Advantage Investment Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-83	Closed	-$1K	–	1016
2018 Q4	$1K	Sell	83 -5,100	-98%	-$89.8K	﹤0.01%	976
2018 Q3	$111K	Buy	5,183 +5,162	+24,581%	+$157K	0.07%	260
2018 Q2	$1K	Hold	21	–	–	﹤0.01%	933
2018 Q1	$1K	Hold	21	–	–	﹤0.01%	977
2017 Q4	$2K	Hold	21	–	–	﹤0.01%	938
2017 Q3	$2K	Sell	21 -556	-96%	-$42.6K	﹤0.01%	966
2017 Q2	$38K	Buy	577 +556	+2,648%	+$68.8K	0.01%	449
2017 Q1	$4K	Sell	21 -906	-98%	-$129K	﹤0.01%	839
2016 Q4	$86K	Sell	927 -136	-13%	-$15.3K	0.03%	242
2016 Q3	$144K	Sell	1,063 -153	-13%	-$15.2K	0.05%	171
2016 Q2	$123K	Buy	1,216 +117	+11%	+$14.5K	0.06%	197
2016 Q1	$180K	Buy	+1,099	New	+$223K	0.08%	144

Other funds holding LUMO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Advantage Investment Management's LUMO Position: Q1 2019 in Review

Advantage Investment Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2019, closing a stake of 83 shares — an estimated $1K sold.

Advantage Investment Management first reported a position in LUMO in Q1 2016 and held it in 12 quarters. The position peaked at $180K in Q1 2016. 82 funds tracked by Wall St. Rank hold LUMO as of Q1 2019.

Advantage Investment Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Advantage Investment Management sold 83 Lumos Pharma, Inc. Common Stock shares in Q1 2019, an estimated $1K.
Advantage Investment Management first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2016 and held it in 12 quarters.
Advantage Investment Management's Lumos Pharma, Inc. Common Stock position peaked at $180K in Q1 2016.
82 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2019.

Based on Advantage Investment Management's 13F filing for Q1 2019, filed 15 May 2019.